Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950.HK) has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals, Inc. for a total consideration of $15 million (approximately HKD 117 million) [1][2] Group 1: Acquisition Details - The assets being acquired include nearly all assets associated with Alexza's business, primarily the Staccato® platform technology, which is an inhalation drug delivery technology, along with related intellectual property, product pipeline, inventory, and contractual rights [2] - Key products involved in the acquisition include the approved Adasuve® and the late-stage development Staccato® alprazolam (for epilepsy), as well as other early-stage pipeline products [2] Group 2: Strategic Implications - The acquisition allows Lee's Pharmaceutical to fully own the clinically validated Staccato® inhalation drug delivery technology platform, which complements its existing product pipeline, including the developing Staccato®-based drugs [2] - The company will benefit from multiple research and development projects, including those targeting central nervous system diseases, and will avoid future royalty payments [2] - Through a licensing agreement with UCB, the company may receive up to $60.5 million in milestone payments, tiered royalties on sales, and manufacturing revenue in the future [2]

Core Viewpoint - The company has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million, which aligns with its strategy to expand its innovative drug delivery technology portfolio and global outreach [1][2]. Group 1: Acquisition Details - The buyer, Nova Pneuma Incorporated, a wholly-owned subsidiary of the company, will acquire all assets related to Alexza's business, including properties, equipment, materials, patents, and other intellectual property [1]. - The total purchase price for the assets is set at $15 million [1]. Group 2: Strategic Alignment - The acquisition supports the company's strategy to expand its product portfolio through the Staccato® platform, which has a wide range of therapeutic potential [2]. - The assets acquired are expected to complement the existing product pipeline and create synergies [2]. - The agreement with UCB, a leading biopharmaceutical company in the epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2].

Group 1 - The company, Lee's Pharmaceutical Holdings Limited, announced an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million [1] - The acquired assets include all properties, equipment, materials (including work-in-progress), patents, intellectual property, technical know-how, rights, and assigned contracts associated with Alexza's business [1] Group 2 - The acquisition aligns with the company's strategy to expand its innovative drug delivery technology portfolio through the Staccato platform, which covers a wide range of indications [2] - The assets will complement the company's existing product pipeline and create synergies, enhancing value for the company and its shareholders [2] - The agreement with UCB, a leading biopharmaceutical company in the global epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2]

Group 1 - The company Li's Pharmaceutical (00950) announced an asset purchase agreement with Nova Pneuma Incorporated to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million [1] - The acquired assets include all properties, equipment, materials (including work-in-progress), patents, intellectual property, technical know-how, rights, and assigned contracts associated with Alexza's business [1] Group 2 - The acquisition aligns with the company's strategy to expand its innovative drug delivery technology portfolio through the Staccato platform, which covers a wide range of indications [2] - The acquired assets are expected to create value for the company and its shareholders, with a focus on Staccato One Breath Technology, which has broad therapeutic potential [2] - The agreement with UCB, a leading biopharmaceutical company in the global epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 須予披露交易 收購資產 資產購買協議 董 事 會 欣 然 宣 佈，於 二 零 二 五 年 十 二 月 八 日（交 易 時 段 後），買 方（本 公 司 的 間 接 全 資 附 屬 公 司）、本 公 司、賣 方 及 賣 方 母 公 司 訂 立 資 產 購 買 協 議，據 此，買 方同意收購而賣方同意出售與Alexza業 務 有 關 的 所 購 資 產，代 價 為15,000,000 美 元（相 等 於 約117,000,000港 元）。 上市規則的含義 由於有關資產購買協議及當中擬進行的交易的一個或多個適用百分比率多 於5%但少於25%，故 根 據 上 市 規 則 第 十 四 章，該 交 易 ...

Core Viewpoint - The company, Degute (300950), has announced the termination of its major asset restructuring plan, which involved the acquisition of control over Haowei Technology, a software and IT service provider [2][3]. Group 1: Termination of Restructuring - On December 3, 2025, Degute's board approved the termination of the asset restructuring plan, stating that no formal agreements had been signed with the transaction parties [2]. - The termination will not adversely affect the company's normal business operations or harm the interests of shareholders, particularly minority shareholders [2]. Group 2: Background of the Restructuring - The restructuring plan was initially announced on June 29, 2025, with the intention to acquire Haowei Technology, which provides digital solutions to global telecom operators and enterprise clients [2]. - The company faced challenges in forming a satisfactory proposal for all parties involved, leading to the decision to terminate the transaction [3]. Group 3: Stock Performance and Financials - Following the announcement of the restructuring, Degute's stock was suspended and later resumed trading on July 14, 2025, experiencing a 58.96% increase over three trading days [3]. - However, after the announcement of the termination, the stock price declined significantly, dropping over 40% from its peak earlier in the year [3]. - For the first three quarters of the year, Degute reported a revenue of 382 million yuan, a year-on-year decrease of 9.29%, and a net profit attributable to shareholders of 72 million yuan, down 26.39% year-on-year [3].

Core Viewpoint - The news highlights the recent stability of tin prices above 300,000 yuan per ton and the positive performance of companies in the tin industry, driven by supply constraints and increasing demand from emerging sectors like semiconductors and consumer electronics [1][5][7]. Tin Price and Market Dynamics - Tin futures reached a three-and-a-half-year high, with the main contract peaking at 314,100 yuan per ton, marking a 2.72% increase [5][18]. - The average spot price of tin on December 3 was 309,700 yuan per ton, up 5,630 yuan from the previous trading day, maintaining above 300,000 yuan for five consecutive days [5][18]. - The rise in tin prices is attributed to tight supply from Myanmar and positive macroeconomic expectations, including a high probability of a Federal Reserve interest rate cut [7][20]. Demand Drivers - The demand for tin is primarily driven by the semiconductor industry, which is expected to see a 19.1% increase in global sales in 2024, reaching $627.6 billion [7][20]. - Tin solder demand is projected to grow at a rate of 5% to 7% in 2025, supported by the recovery of the global economy and advancements in new industries [7][20]. Company Performance and Stock Market Reaction - Seven listed companies in the A-share market are involved in the tin industry, with significant investor interest due to rising tin prices [8][21]. - The average stock price increase for tin-related companies this year is 113.08%, with notable gains from companies like Xingye Silver Tin and Shengtun Mining, which saw increases of 226.33% and 160.32%, respectively [8][21]. - In the first three quarters, these companies collectively achieved a net profit of 43.314 billion yuan, a year-on-year increase of 47.47% [9][22]. Individual Company Highlights - Zijin Mining reported a net profit of 37.864 billion yuan in the first three quarters, up 55.45% year-on-year, with significant tin reserves [9][22][23]. - Xiyang Tin achieved a net profit of 1.745 billion yuan, reflecting a 35.99% increase year-on-year, maintaining its position as the largest tin producer globally [10][23]. - Institutional interest is high, with Zijin Mining and Xiyang Tin receiving the most ratings from analysts, indicating strong market confidence [10][23][24].

Core Viewpoint - The company, Degute, announced the termination of its major asset restructuring plan, resulting in a nearly 44% drop in stock price since October 14 [2][8]. Group 1: Termination of Asset Restructuring - On December 3, Degute's board approved the termination of the plan to acquire 100% of Haowei Cloud Computing Technology Co., Ltd. through a combination of share issuance and cash payment [2][5]. - The company aimed to enter the digital transformation sector through this acquisition, which was expected to constitute a significant asset restructuring and related party transaction [5]. - Despite ongoing discussions and negotiations regarding the transaction terms, the parties could not reach an agreement on key aspects such as transaction price and performance commitments [5][6]. Group 2: Financial Performance - For the first three quarters of the year, Degute reported revenue of 382 million yuan, a year-on-year decrease of 9.29%, and a net profit attributable to shareholders of 72.26 million yuan, down 26.39% year-on-year [7]. - As of December 3, Degute's stock closed at 22.8 yuan, reflecting a 43.8% decline from its peak on October 14, with a market capitalization of 3.5 billion yuan [8].

Core Viewpoint - DeguTech announced the termination of its major asset restructuring plan, resulting in a nearly 44% drop in stock price since October 14 [1][5]. Group 1: Termination of Restructuring - On December 3, DeguTech's board approved the termination of the plan to acquire 100% of Haowei Cloud Computing Technology Co., Ltd. through share issuance and cash payment [4][5]. - The company had initially aimed to enter the digital transformation sector through this acquisition to build a differentiated advantage [4][5]. - Despite ongoing discussions, DeguTech and the transaction counterparties could not reach an agreement on key terms such as transaction price and scheme [4][5]. Group 2: Financial Performance - In the first three quarters of the year, DeguTech reported revenue of 382 million yuan, a year-on-year decrease of 9.29%, and a net profit attributable to shareholders of 72.26 million yuan, down 26.39% year-on-year [5]. - As of December 3, DeguTech's stock closed at 22.8 yuan, down 43.8% from its peak of 40.5 yuan on October 14, with a market capitalization of 3.5 billion yuan [5].

Core Viewpoint - The company, Degute (300950), has officially terminated its plan for a major asset restructuring involving the acquisition of Haowei Cloud Computing Technology Co., Ltd. due to failure to reach an agreement on key terms between the parties involved [2][3]. Group 1: Restructuring Process - The restructuring process began in June 2023, with the company planning to acquire 100% of Haowei Technology's shares through a combination of stock issuance and cash payment [2]. - The company’s stock was suspended from trading on June 30, 2023, and resumed trading on July 14, 2023, after the board approved the transaction proposal [3]. - Following the announcement of the restructuring plan, the market had high expectations for the company's transformation, leading to a peak stock price increase of 82% after the resumption of trading [3]. Group 2: Financial Performance and Challenges - Degute faced significant challenges, including intensified industry competition and limited market space, leading to a 26.39% year-on-year decline in net profit for the first three quarters of 2025 [2]. - The financial data from Haowei Technology indicated projected net profits of 202 million yuan and 205 million yuan for 2023 and 2024, respectively, but a seasonal loss of 133 million yuan in the first quarter of 2025, which contributed to valuation disagreements [3]. Group 3: Termination of Restructuring - The company decided to terminate the restructuring to protect the interests of the company and its shareholders, as it was challenging to form a satisfactory plan within the effective time window [4]. - Following the termination, the company signed a release agreement with the transaction parties, stating that no party would bear liability for breach of contract due to the absence of a formal agreement [4]. - The termination of the restructuring is not expected to adversely affect the company's normal business operations, as evidenced by a significant increase of 1447.22% in net cash flow from operating activities for the first three quarters, totaling 60.55 million yuan [4].